Loyal, a clinical-stage animal health company developing lifespan extension drugs for dogs, announced that it has raised $100M in Series C funding. The next generation of Laura Deming's Longevity Fund, led the round. Baillie Gifford also participated alongside existing investors, bringing the total investment in Loyal to over $250M since its founding in late 2019.